Samsung Biologics hit a new all-time high. With the bio sector emerging as the leading industry in the domestic stock market, many investors interpret that Samsung Biologics will continue its performance growth trend.
Samsung Biologics shares were traded at 1,181,000 won on the KOSPI market at 10:49 a.m. on the 11th. The stock price rose by 4.51% (51,000 won) compared to the previous day. During the session, the stock price surged to 1,187,000 won, marking an all-time high.
Securities firms expect that the full operation of Samsung Biologics' fourth plant this year will lead to an upward performance curve. They predict that Samsung Biologics' consolidated revenue and operating profit will average 5.4666 trillion won and 1.5871 trillion won this year, which is about 20% higher than last year's provisional results.
Target stock prices have also been revised upward. According to financial information provider FnGuide, 18 securities firms that have expressed investment opinions on Samsung Biologics this year provided an average target stock price of 1,288,333 won. Mirae Asset Securities and KB Securities have raised their target prices to 1,350,000 won.